ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Transcatheter Mitral Valve Replacement for Patients With Symptomatic Mitral Regurgitation. A Global Feasibility Trial

Friday, January 27, 2017

Submitted by

Source

Source Name: Journal of the American College of Cardiology

Author(s)

David W.M. Muller, Robert Saeid Farivar, Paul Jansz, Richard Bae, Darren Walters, Andrew Clarke, Paul A. Grayburn, Robert C. Stoler, Gry Dahle, Kjell A. Rein, Marty Shaw, Gregory M. Scalia, Mayra Guerrero, Paul Pearson, Samir Kapadia, Marc Gillinov, Augusto Pichard, Paul Corso, Jeffrey Popma, Michael Chuang, Philipp Blanke, Jonathon Leipsic, Paul Sorajja, Tendyne Global Feasibility Trial Investigators

Results are reported of a global feasibility study in which 30 patients at high risk for mitral valve surgery were enrolled at 8 study sites. Patients underwent transapical mitral valve replacement with a Tendyne transcatheter mitral valve. A mitral prosthesis was successfully implanted in 93%. In these 28 patients, the residual MR (valvular or paravalvular) was grade 0 in all but 1 patient and there was no LVOT obstruction. There was no device embolization or cardiac perforation. At 30 days, there was only one death (3.3%). Repeat echocardiography showed no evidence of prosthesis dysfunction. There were no strokes, no myocardial infarctions, and no additional device-related complications during hospitalization. The authors conclude that transcatheter mitral valve replacement using a prosthesis specifically designed for the mitral valve is feasible and can be performed safely.

Add comment

Log in or register to post comments